PT3292116T - Ácidos 3-aril-4-amido-bicíclico [4,5,0] hidroxâmicos como inibidores de hdac - Google Patents

Ácidos 3-aril-4-amido-bicíclico [4,5,0] hidroxâmicos como inibidores de hdac

Info

Publication number
PT3292116T
PT3292116T PT167043579T PT16704357T PT3292116T PT 3292116 T PT3292116 T PT 3292116T PT 167043579 T PT167043579 T PT 167043579T PT 16704357 T PT16704357 T PT 16704357T PT 3292116 T PT3292116 T PT 3292116T
Authority
PT
Portugal
Prior art keywords
amido
bicyclic
aryl
hdac inhibitors
hydroxamic acids
Prior art date
Application number
PT167043579T
Other languages
English (en)
Original Assignee
Valo Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valo Health Inc filed Critical Valo Health Inc
Publication of PT3292116T publication Critical patent/PT3292116T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT167043579T 2015-02-02 2016-02-02 Ácidos 3-aril-4-amido-bicíclico [4,5,0] hidroxâmicos como inibidores de hdac PT3292116T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562110716P 2015-02-02 2015-02-02
US201562205438P 2015-08-14 2015-08-14

Publications (1)

Publication Number Publication Date
PT3292116T true PT3292116T (pt) 2022-01-14

Family

ID=55353351

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167043579T PT3292116T (pt) 2015-02-02 2016-02-02 Ácidos 3-aril-4-amido-bicíclico [4,5,0] hidroxâmicos como inibidores de hdac

Country Status (27)

Country Link
US (32) US10112915B2 (pt)
EP (3) EP3253747B1 (pt)
JP (1) JP6668362B2 (pt)
KR (1) KR102633628B1 (pt)
CN (3) CN114057765A (pt)
AU (4) AU2016215431B2 (pt)
BR (1) BR112017016493B1 (pt)
CA (2) CA2975605C (pt)
CL (1) CL2017001968A1 (pt)
CO (1) CO2017007863A2 (pt)
DK (1) DK3292116T3 (pt)
EA (2) EA201792673A1 (pt)
EC (1) ECSP17055491A (pt)
ES (2) ES2903523T3 (pt)
HK (2) HK1251550A1 (pt)
HU (1) HUE057623T2 (pt)
IL (4) IL280856B (pt)
MA (1) MA42032A (pt)
MX (2) MX2017009950A (pt)
MY (1) MY191591A (pt)
PH (1) PH12017501383A1 (pt)
PL (1) PL3292116T3 (pt)
PT (1) PT3292116T (pt)
SA (1) SA517382027B1 (pt)
SG (4) SG11201708622UA (pt)
TW (6) TW201636333A (pt)
WO (4) WO2016126725A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42032A (fr) 2015-02-02 2018-03-14 Forma Therapeutics Inc Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
CN107531660A (zh) 2015-03-13 2018-01-02 福马治疗股份有限公司 作为HDAC8抑制剂的α‑肉桂酰胺化合物和组合物
TW201711999A (zh) 2015-09-03 2017-04-01 佛瑪治療公司 ﹝６，６﹞稠合雙環組蛋白脫乙醯基酶８（ｈｄａｃ８）抑制劑
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CA3063934A1 (en) * 2017-05-17 2018-11-22 Denali Therapeutics Inc. Kinase inhibitors and uses thereof
WO2019034532A1 (en) * 2017-08-15 2019-02-21 Bayer Aktiengesellschaft 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamides
US20210403479A1 (en) 2018-11-08 2021-12-30 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
CN111848591B (zh) * 2019-04-25 2022-03-18 成都先导药物开发股份有限公司 Hdac抑制剂及其制备方法和用途
BR112022005595A2 (pt) 2019-09-27 2022-07-19 Takeda Pharmaceuticals Co Composto, medicamento, métodos para inibir histona deacetilase 6 e para profilaxia ou tratamento de doença de alzheimer ou paralisia supranuclear progressiva em um mamífero, e, uso de composto
CN113527206B (zh) * 2020-04-17 2022-12-30 上海中泽医药科技有限公司 一种苯并氮杂环类化合物、其制备方法及用途
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
CN112691706A (zh) * 2020-12-23 2021-04-23 中触媒新材料股份有限公司 一种乙醇制乙腈催化剂的再生方法
CA3215958A1 (en) 2021-04-23 2022-10-27 Tenaya Therapeutics, Inc. Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy
AU2022270657A1 (en) 2021-05-04 2023-11-16 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
JP2024533236A (ja) * 2021-09-06 2024-09-12 タイペイ・メディカル・ユニバーシティ ヒストン脱アセチル化酵素６及び熱ショックタンパク質９０の二重阻害剤
WO2023081328A1 (en) * 2021-11-04 2023-05-11 Valo Health, Inc. Histone deacetylase 6 inhibitor compounds and uses thereof
WO2024104822A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted tetrahydrobenzodiazepine as fungicides
WO2024104823A1 (en) 2022-11-16 2024-05-23 Basf Se New substituted tetrahydrobenzoxazepine

Family Cites Families (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557425C2 (de) 1975-12-19 1987-03-19 C.H. Boehringer Sohn, 6507 Ingelheim 11-Oxo-11-H-pyrido[2,1-b]-chinazolin-2-carbonsäure und ihre Salze, Verfahren zu ihrer Herstellung und Arzneimittel
DE3704203A1 (de) 1987-02-11 1988-08-25 Boehringer Ingelheim Kg Verwendung von oxochinazolinderivaten bei der behandlung der hyperurikaemie
US5244911A (en) 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz(cd)indoles and pharmaceutical use thereof
US5153185A (en) 1991-04-16 1992-10-06 Merck & Co., Inc. 2-phenanthridonyl carbapenems
US5294610A (en) 1992-10-15 1994-03-15 Merck & Co. Inc. 2-(aza-9-fluorenonyl)carbapenem antibacterial agents
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
WO1994014777A1 (en) 1992-12-28 1994-07-07 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
AU6087194A (en) 1993-01-15 1994-08-15 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors
US5384317A (en) 1993-08-02 1995-01-24 Merck & Co., Inc. Bridged biphenyl carbapenem compounds, compositions containing such compounds and methods of use
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
CA2176808A1 (en) 1993-11-18 1995-05-26 Scott Hultgren Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
US6872542B1 (en) 1993-11-18 2005-03-29 Siga Pharmaceuticals, Inc. Treatment or prophylaxis of diseases caused by pilus-forming bacteria
US6110913A (en) 1994-01-04 2000-08-29 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
US5532261A (en) 1994-12-12 1996-07-02 Merck & Co., Inc. Carbapenem antibiotics, compositions containing such compounds and methods of use
US5719144A (en) 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
KR100423590B1 (ko) 1995-08-02 2004-09-10 호따. 우리아치에씨아. 에세. 아. 항진균활성을갖는신규피리미돈유도체
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
WO1997048786A1 (de) 1996-06-19 1997-12-24 Call Hans Peter Mehrkomponentensystem zur verwendung mit waschaktiven substanzen
DE19726241A1 (de) 1997-06-20 1998-12-24 Call Krimhild Erweitertes enzymatisches Multikomponentensystem zur Behandlung von Abwässern, zur Herstellung von Holzverbundstoffen, zum Deinken von Altpapier, Colour stripping von Altpapier, zum Einsatz als Oxidationssystem bei der organischen Synthese und zum Einsatz bei der Kohleverflüssigung
IL121748A0 (en) 1997-09-11 1998-02-22 Yeda Res & Dev Vanadium complexes of hydroxamates and pharmaceutical compositions comprising them
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
WO1999067238A2 (en) 1998-06-25 1999-12-29 Sepracor, Inc. Tetrahydroquinoline-indole derivatives antimicrobial agents, their uses and compositions containing them
JP2000044562A (ja) 1998-07-31 2000-02-15 Kyowa Hakko Kogyo Co Ltd ピロロフタルイミド誘導体
US6288099B1 (en) 1998-12-04 2001-09-11 American Home Products Corporation Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
EP1135393A2 (en) 1998-12-04 2001-09-26 American Home Products Corporation Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
JP2000357809A (ja) 1999-06-15 2000-12-26 Fuji Photo Film Co Ltd 光電変換材料、光電変換素子及びポリメチン色素
JP4162106B2 (ja) 1999-06-17 2008-10-08 富士フイルム株式会社 光電変換素子および光電気化学電池ならびに金属錯体色素
US6476019B1 (en) 1999-08-13 2002-11-05 Sepracor Inc. Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
FR2809391B1 (fr) 2000-05-29 2003-05-09 Rhodia Chimie Sa Nouveau mortier phosphomagnesien, procede d'obtention de ce mortier
AU2002227135B2 (en) 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
AU2002214222A1 (en) 2000-11-01 2002-05-15 Yeda Research And Development Co..Ltd. Pharmaceutical compositions comprising organic vanadium complexes for treatment of ischemia
HUP0400651A2 (hu) 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
US7214690B2 (en) 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
IN192526B (pt) 2001-09-25 2004-04-24 Ranbaxy Lab
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
DE60320957D1 (en) 2002-03-13 2008-06-26 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase-inhibitoren
WO2003087059A2 (en) 2002-04-08 2003-10-23 Sun Pharmaceutical Industries Limited (e)-oxime ether derivative of 5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one
TW200404796A (en) 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
AU2003290079A1 (en) 2002-12-20 2004-07-14 Basf Aktiengesellschaft Pesticidal dibenzo(hetero)azepine derivatives
JP2004210716A (ja) 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体
WO2004063156A1 (en) 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
US7241775B2 (en) 2003-03-24 2007-07-10 Sanofi-Aventis Deutschland Gmbh Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
PT1622569E (pt) 2003-04-24 2016-03-03 Incyte Corp Derivados de aza espiro alcanos como inibidores de metaloproteases
GB0313766D0 (en) 2003-06-13 2003-07-23 Xenova Ltd Pharmaceutical compounds
WO2005028478A1 (en) 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
CN101010298A (zh) * 2004-04-05 2007-08-01 默克Hdac研究有限责任公司 组蛋白脱乙酰酶抑制剂前药
WO2005108367A1 (en) * 2004-05-03 2005-11-17 Envivo Pharmaceuticals, Inc. Compounds for treatment of neurodegenerative diseases
JP4879889B2 (ja) 2004-05-17 2012-02-22 テイボテク・フアーマシユーチカルズ・リミテツド ４−置換−１，５−ジヒドロ−ピリド［３，２−ｂ］インドール−２−オン
AU2005251943A1 (en) 2004-06-09 2005-12-22 Altana Pharma Ag Substituted tricyclic benzimidazoles
US7470722B2 (en) 2004-06-10 2008-12-30 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
AR051041A1 (es) 2004-10-04 2006-12-13 Altana Pharma Ag Bencimidazoles triciclicos condensados
UY29198A1 (es) 2004-11-09 2006-05-31 Cancer Rec Tech Ltd Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
WO2006065842A2 (en) 2004-12-13 2006-06-22 Synta Pharmaceuticals Corp. 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof
EP1845970B1 (en) 2005-01-31 2013-08-28 Cephalon, Inc. Tumor necrosis factor inhibitors
EP2491926B1 (en) 2005-03-22 2018-05-09 President and Fellows of Harvard College Treatment of protein degradation disorders
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
AR057061A1 (es) 2005-06-16 2007-11-14 Altana Pharma Ag Espiro-bencimidazoles farmaceuticamente activos y su uso en la fabricacion de medicamentos
BRPI0611948A2 (pt) 2005-06-17 2010-10-13 Wyeth Corp compostos úteis como inibidores de serotonina e agonistas de antagonista de 5-ht1a
WO2006136552A2 (en) 2005-06-22 2006-12-28 Nycomed Gmbh Process for the production of intermadiates for the preparation of tricyclic benzimidazoles
ATE455103T1 (de) 2005-06-24 2010-01-15 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
WO2007023135A1 (en) 2005-08-22 2007-03-01 Nycomed Gmbh Isotopically substituted benzimidazole derivatives
US20070155730A1 (en) 2005-08-26 2007-07-05 Methylgene, Inc. Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase
GB0518237D0 (en) 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5249772B2 (ja) 2005-11-22 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション キナーゼの阻害剤として有用な三環式化合物
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
CA2632444A1 (en) 2005-12-19 2007-06-28 Boehringer Ingelheim International Gmbh Use of aminoalcohol derivatives for the treatment of overactive bladder
DE102005061655A1 (de) 2005-12-22 2007-06-28 Merck Patent Gmbh Diazepinone
PE20071241A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
CA2642273C (en) 2006-02-14 2016-09-20 President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
US8338416B2 (en) 2006-03-16 2012-12-25 Pharmacylics, Inc. Indole derivatives as inhibitors of histone deacetylase
US20080004282A1 (en) 2006-04-10 2008-01-03 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
JP2010512303A (ja) 2006-06-12 2010-04-22 ビアメト ファーマシューティカルズ，インク． 金属結合部分をターゲティング部分と組み合わせて用いるメタロヒドロラーゼ阻害剤
WO2007143822A1 (en) 2006-06-14 2007-12-21 Methylgene Inc. Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
CN101108859A (zh) 2006-07-17 2008-01-23 上海恒瑞医药有限公司 长春碱类化合物、其制备方法及其在医药上的用途
WO2008014307A2 (en) 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
US20100173332A1 (en) 2006-09-07 2010-07-08 Auckland Uniservices Limited Method for the Fluorescent Detection of Nitroreductase Activity Using Nitro-Substituted Aromatic Compounds
WO2008048648A2 (en) 2006-10-17 2008-04-24 Acadia Pharmaceuticals Inc. Cb1-modulating compounds and their use
WO2008046155A1 (en) 2006-10-20 2008-04-24 Dia-B Tech Limited Methods for regulating glucose homeostasis and agents therefor
CN103275067B (zh) 2006-10-28 2015-09-02 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
WO2008053131A1 (en) 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
WO2008061160A1 (en) 2006-11-14 2008-05-22 Pharmacyclics, Inc. Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions
US7820711B2 (en) 2006-11-14 2010-10-26 Pharmacyclics Inc. Uses of selective inhibitors of HDAC8 for treatment of T-cell proliferative disorders
EP2091533B1 (en) 2006-12-08 2012-11-28 Merck Sharp & Dohme Corp. Constrained spirocyclic compounds as cgrp receptor antagonists
WO2008071765A1 (en) 2006-12-14 2008-06-19 Nycomed Gmbh Pharmaceutically active spiro-substituted benzimidazole derivatives
WO2008074858A1 (en) 2006-12-21 2008-06-26 Nycomed Gmbh Intermediates and process for the production of 5-substituted tricyclic benzimidazoles
CA2677649A1 (en) 2007-02-09 2008-08-21 Forest Laboratories Holdings Limited Bioavailable formulations of heterocyclic compounds
WO2008101186A1 (en) 2007-02-15 2008-08-21 The J. David Gladstone Institutes Inhibitors for hdac8
DE102007013856A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydropyrrolochinoline
DE102007013855A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
DE102007013854A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Tetrahydrochinoline
US20090105283A1 (en) 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20080255161A1 (en) 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
CN101784516B (zh) 2007-06-13 2014-07-02 百时美施贵宝公司 作为凝血因子抑制剂的二肽类似物
JP5412429B2 (ja) 2007-07-23 2014-02-12 クレストーン・インコーポレーテッド 抗細菌性アミド及びスルホンアミド置換複素環式尿素化合物
EP2240483B8 (en) 2008-01-09 2013-04-03 Array Biopharma, Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8987468B2 (en) 2008-02-04 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
WO2009100406A2 (en) 2008-02-07 2009-08-13 Synta Pharmaceuticals Corp. Topical formulations for the treatment of psoriasis
JP2009191041A (ja) 2008-02-18 2009-08-27 Univ Of Tokyo ヒドロキシメチルケトン誘導体
EP2100879A1 (en) 2008-03-13 2009-09-16 4Sc Ag Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
EP2311840A1 (en) 2009-10-13 2011-04-20 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
US8980877B2 (en) 2008-04-15 2015-03-17 Dac S.R.L. Spirocyclic derivatives as histone deacetylase inhibitors
EP2110377A1 (en) 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
WO2009137503A1 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Hdac inhibitors and uses thereof
WO2009137492A1 (en) 2008-05-05 2009-11-12 Abbott Laboratories Heteroaryl-fused macrocyclic pyrimidine derivatives
EP2303888B1 (en) 2008-06-12 2015-05-06 President and Fellows of Harvard College Compounds for antimicrobial intervention
US8058427B2 (en) 2008-06-12 2011-11-15 National Health Research Institutes Coumarin compounds and their use for treating cancer
EP2330894B8 (en) 2008-09-03 2017-04-19 BioMarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
ES2459195T3 (es) 2008-09-11 2014-05-08 Amgen Inc. Compuestos de anillo espiro-tetracíclico como moduladores de beta-secretasa y métodos de uso
WO2010042475A1 (en) 2008-10-07 2010-04-15 Schering Corporation Spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
US9040528B2 (en) 2008-10-14 2015-05-26 Astrazeneca Ab Chemical compounds 542
BRPI0920180B1 (pt) 2008-10-14 2021-10-26 Entasis Therapeutics Limited Compostos herecíclicos substituídos, uso dos mesmos e composiçâo farmacêutica compreendendo os ditos compostos
JP2012505881A (ja) 2008-10-15 2012-03-08 ギリアード サイエンシーズ， インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するための３−ヒドロキナゾリン−４−オン誘導体
WO2010054278A2 (en) 2008-11-10 2010-05-14 Schering Corporation Compounds for the treatment of inflammatory disorders
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010056038A2 (ko) 2008-11-11 2010-05-20 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
WO2010088414A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
ES2573088T3 (es) 2009-03-27 2016-06-06 Merck Sharp & Dohme Corp. Inhibidores de la replicación del virus de la hepatitis C
CN102388051A (zh) 2009-04-09 2012-03-21 贝林格尔.英格海姆国际有限公司 Hiv复制抑制剂
WO2010125469A1 (en) 2009-04-29 2010-11-04 Glenmark Pharmaceuticals, S.A. Pyrimidinedione-fused heterocyclic compounds as trpa1 modulators
US9096518B2 (en) 2009-06-22 2015-08-04 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2010151317A1 (en) 2009-06-22 2010-12-29 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
CA2766550C (en) 2009-06-23 2017-04-11 The Translational Genomics Research Intstitute Benzamide derivatives
EP2266985A1 (en) 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Tricyclic Pyrimidine Derivatives as Wnt antagonists
WO2011002520A2 (en) 2009-07-02 2011-01-06 Angion Biomedica Corp. Small molecule inhibitors of parp activity
ES2736200T3 (es) 2009-07-22 2019-12-26 Univ Illinois Inhibidores de HDAC y métodos terapéuticos que utilizan los mismos
EP2477493A1 (en) 2009-09-16 2012-07-25 Cylene Pharmaceuticals, Inc. Novel tricyclic protein kinase modulators
AU2010299820A1 (en) 2009-09-28 2012-04-19 F. Hoffmann-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
US8242104B2 (en) 2009-09-28 2012-08-14 F. Hoffman-La Roche Ag Benzoxazepin P13K inhibitor compounds and methods of use
EP2305643A1 (en) 2009-10-02 2011-04-06 Ikerchem, S.L. New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers
US9221773B2 (en) 2009-12-22 2015-12-29 The Translational Genomics Research Institute Benzamide derivatives
US8198290B2 (en) 2009-12-23 2012-06-12 Berry And Associates, Inc. Methoxatin derivatives
US20130040998A1 (en) 2010-01-08 2013-02-14 Dana-Farber Cancer Institute, Inc. Fluorinated hdac inhibitors and uses thereof
AU2011205283B2 (en) 2010-01-13 2014-07-10 Tempero Pharmaceuticals, Inc. Compounds and methods
JP2011148714A (ja) 2010-01-19 2011-08-04 Nippon Soda Co Ltd 病害防除方法
JP5940984B2 (ja) 2010-01-22 2016-06-29 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． タンパク質デアセチラーゼ阻害剤としてのリバースアミド化合物とその使用方法
US8519122B2 (en) 2010-02-12 2013-08-27 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US8546588B2 (en) 2010-02-26 2013-10-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011106632A1 (en) 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011130163A1 (en) 2010-04-12 2011-10-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
JO3131B1 (ar) 2010-04-27 2017-09-20 Glaxosmithkline Llc مركبات كيميائية
WO2011146591A1 (en) 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011159857A1 (en) 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
WO2012012322A1 (en) 2010-07-19 2012-01-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012012320A1 (en) 2010-07-19 2012-01-26 Millenium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2598133A4 (en) 2010-07-30 2014-03-05 Univ California METHOD AND THERAPEUTIC SUBSTANCE FOR TREATMENT AND REGULATION OF MEMORY FORMATION
US8471026B2 (en) 2010-08-26 2013-06-25 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
JP5815033B2 (ja) 2010-09-09 2015-11-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌治療用新規ｎ−ヒドロキシ−ベンズアミド
WO2012045804A1 (en) 2010-10-08 2012-04-12 Vib Vzw Hdac inhibitors to treat charcot-marie-tooth disease
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
WO2012054332A1 (en) 2010-10-18 2012-04-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
BR112013009614A2 (pt) 2010-10-22 2016-07-19 Centre Nat Rech Scient conjugados de pochoxime úteis para o tratamento de patologias relacionadas à hsp90
ES2568260T3 (es) 2010-11-16 2016-04-28 Acetylon Pharmaceuticals, Inc. Compuestos de pirimidin hidroxi amida como inhibidores de proteína desacetilasa y métodos de uso de los mismos
CN102558200A (zh) 2010-12-21 2012-07-11 复旦大学 长春碱类衍生物、其制备方法及其在医药上的用途
WO2012088015A2 (en) 2010-12-22 2012-06-28 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012085003A1 (en) 2010-12-22 2012-06-28 Katholieke Universiteit Leuven, K.U. Leuven R&D 2-hydroxyisoquinoline-1,3(2h,4h)-diones and related compounds useful as hiv replication inhibitors
WO2012096832A2 (en) 2011-01-12 2012-07-19 Crystal Biopharmaceutical Llc Hdac inhibiting derivatives of camptothecin
US9029391B2 (en) 2011-01-24 2015-05-12 Viiv Healthcare Uk Limited Isoquinoline compounds and methods for treating HIV
EP2670733B1 (en) 2011-02-01 2019-04-10 The Board of Trustees of the University of Illionis N-hydroxybenzamide derivatives as hdac inhibitors and therapeutic methods using the same
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
WO2012109165A1 (en) 2011-02-07 2012-08-16 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
JP2014505113A (ja) 2011-02-14 2014-02-27 アルカーメス，インコーポレイテッド 末梢作用性μオピオイドアンタゴニスト
WO2012112462A1 (en) 2011-02-15 2012-08-23 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
WO2012110860A1 (en) 2011-02-17 2012-08-23 Glenmark Pharmaceuticals S.A. TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
WO2012117421A1 (en) 2011-03-02 2012-09-07 Orchid Research Laboratories Ltd Histone deacetylase inhibitors
WO2012126901A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
CN102838625B (zh) 2011-06-22 2015-04-15 中国科学院上海药物研究所 四氢吡啶并噻唑类化合物、其制备方法、包含该化合物的药物组合物及其用途
US20150197497A1 (en) 2011-06-24 2015-07-16 Dana-Farber Cancer Institute, Inc. Selective inhibitors of histone deacetylase isoform 6 and methods thereof
WO2013006408A1 (en) 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013008162A1 (en) 2011-07-08 2013-01-17 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013013113A2 (en) 2011-07-20 2013-01-24 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
PL2750677T3 (pl) 2011-08-30 2017-12-29 Chdi Foundation, Inc. Inhibitory 3-monooksygenazy kinureninowej, kompozycje farmaceutyczne i sposoby ich stosowania
US9296759B2 (en) 2011-09-21 2016-03-29 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US20140241990A1 (en) 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
WO2013052110A1 (en) 2011-10-03 2013-04-11 The Trustees Of Columbia University In The City Of New York Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
JP6224600B2 (ja) 2011-10-18 2017-11-01 エコール ポリテクニーク フェデラル ドゥ ローザンヌ（エーペーエフエル） 電気化学および／または光電子デバイス用化合物
WO2013059582A2 (en) 2011-10-20 2013-04-25 Nupotential, Inc. Small molecule inhibitors of histone deacteylases
SI2788343T1 (sl) 2011-12-11 2019-09-30 Viamet Pharmaceuticals (NC), Inc. Spojine inhibitorja metaloencimov
EP3415148A1 (en) 2011-12-15 2018-12-19 Alkermes Pharma Ireland Limited Compositions of buprenorphine and mu-opioid receptor antagonists
JP6233812B2 (ja) 2012-03-07 2017-11-22 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 選択的ヒストンデアセチラーゼ６阻害剤
GB2503789A (en) 2012-05-15 2014-01-08 Syngenta Participations Ag Quinazoline derivatives as antifungal agents
JP2015527322A (ja) 2012-07-10 2015-09-17 ジョージア ステイト ユニバーシティ リサーチ ファンデーション， インコーポレイテッド アントラキノン類似体ならびにその作製方法および使用方法
US9085586B2 (en) 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
WO2014011911A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014018919A1 (en) 2012-07-27 2014-01-30 The Regents Of The University Of California Seriniquinones, melanoma-specific anticancer agents
BR112015004648A2 (pt) 2012-09-05 2017-07-04 Bayer Cropscience Ag amidas de ácidos bicicloaril carboxílicos com atividade herbicida
CN104781259B (zh) 2012-09-28 2018-06-01 拜耳制药股份公司 抑制bet蛋白的5-芳基三唑并氮杂*
US9040504B2 (en) 2013-01-10 2015-05-26 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014127881A1 (de) 2013-02-25 2014-08-28 Merck Patent Gmbh 2-amino-3,4-dihydrc-chinazolin derivate und ihre verwendung als cathepsin d inhibitoren
US9580400B2 (en) 2013-02-26 2017-02-28 Northeastern University Cannabinergic nitrate esters and related analogs
KR101645379B1 (ko) 2013-04-29 2016-08-03 주식회사 종근당 선택적 히스톤 탈아세틸화 효소 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
EP2991981B1 (en) 2013-04-30 2017-03-01 Boehringer Ingelheim International GmbH Diaminopyrazine compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
US9278963B2 (en) 2013-10-10 2016-03-08 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
RU2660897C2 (ru) 2014-03-12 2018-07-11 Чонг Кун Данг Фармасьютикал Корп. Новые соединения в качестве ингибиторов гистондеацетилазы 6 и содержащие их фармацевтические композиции
MA42032A (fr) 2015-02-02 2018-03-14 Forma Therapeutics Inc Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
GB201505133D0 (en) * 2015-03-26 2015-05-06 Egerton Charles E And Scott Harden Simon Self-propelled water board apparatus
TW201643139A (zh) 2015-04-17 2016-12-16 佛瑪治療公司 作為組蛋白脫乙醯基酶抑制劑之３－螺環－６－異羥肟酸萘滿
PL3362445T3 (pl) 2015-10-12 2023-08-07 Chong Kun Dang Pharmaceutical Corp. Związki będące pochodnymi oksadiazoloamin jako inhibitor deacetylazy histonowej 6 oraz kompozycja farmaceutyczna obejmujące takie związki
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors

Also Published As

Publication number Publication date
MY191591A (en) 2022-06-30
TW201629026A (zh) 2016-08-16
AU2016215431B2 (en) 2020-07-23
AU2020257136A1 (en) 2020-11-19
US10829461B2 (en) 2020-11-10
US20220204461A1 (en) 2022-06-30
PH12017501383A1 (en) 2018-01-08
US10214501B2 (en) 2019-02-26
IL255111A (en) 2018-02-28
US20190119229A1 (en) 2019-04-25
US20190062288A1 (en) 2019-02-28
US20190112279A1 (en) 2019-04-18
IL280856A (en) 2021-04-29
US20190119231A1 (en) 2019-04-25
KR102633628B1 (ko) 2024-02-02
US11279681B2 (en) 2022-03-22
AU2020260523A1 (en) 2020-11-26
US10450284B2 (en) 2019-10-22
US20190112281A1 (en) 2019-04-18
TW202136220A (zh) 2021-10-01
KR20170122759A (ko) 2017-11-06
BR112017016493B1 (pt) 2023-12-12
US10421732B2 (en) 2019-09-24
US20190119235A1 (en) 2019-04-25
US10822316B2 (en) 2020-11-03
US20160221972A1 (en) 2016-08-04
US20190119230A1 (en) 2019-04-25
US20200048211A1 (en) 2020-02-13
US10464910B2 (en) 2019-11-05
MA42032A (fr) 2018-03-14
US10214500B2 (en) 2019-02-26
US10239845B2 (en) 2019-03-26
AU2016215432B2 (en) 2020-07-30
US20190127339A1 (en) 2019-05-02
US10494354B2 (en) 2019-12-03
US10501424B2 (en) 2019-12-10
EP3292116B8 (en) 2021-11-24
US11891365B2 (en) 2024-02-06
IL279830B (en) 2022-08-01
SG10202100916PA (en) 2021-02-25
US10494352B2 (en) 2019-12-03
TW202110813A (zh) 2021-03-16
EP3253747B1 (en) 2019-11-27
TW201636333A (zh) 2016-10-16
CL2017001968A1 (es) 2018-04-13
IL280856B (en) 2022-09-01
US20190119232A1 (en) 2019-04-25
US10414738B2 (en) 2019-09-17
IL255111B (en) 2021-01-31
CN107801396A (zh) 2018-03-13
US20190119234A1 (en) 2019-04-25
US20200002298A1 (en) 2020-01-02
US11274084B2 (en) 2022-03-15
WO2016126721A1 (en) 2016-08-11
US20190016692A1 (en) 2019-01-17
US10464909B2 (en) 2019-11-05
HK1251550A1 (zh) 2019-02-01
EP3253747A1 (en) 2017-12-13
ECSP17055491A (es) 2017-11-30
US10428031B2 (en) 2019-10-01
DK3292116T3 (da) 2022-01-10
US20160222028A1 (en) 2016-08-04
US20190112283A1 (en) 2019-04-18
SG11201706146UA (en) 2017-08-30
US20160221973A1 (en) 2016-08-04
US10988450B2 (en) 2021-04-27
HUE057623T2 (hu) 2022-05-28
TW201643145A (zh) 2016-12-16
TWI776156B (zh) 2022-09-01
CN114057765A (zh) 2022-02-18
CA2990165A1 (en) 2016-08-11
ES2770123T3 (es) 2020-06-30
CO2017007863A2 (es) 2017-10-20
US20190112282A1 (en) 2019-04-18
WO2016126722A1 (en) 2016-08-11
US20210009539A1 (en) 2021-01-14
EA201791747A1 (ru) 2018-01-31
MX2017009950A (es) 2017-11-23
US10377726B2 (en) 2019-08-13
AU2016215432A1 (en) 2017-08-17
JP2018503674A (ja) 2018-02-08
BR112017016493A2 (pt) 2018-04-10
CN107873023A (zh) 2018-04-03
TWI712591B (zh) 2020-12-11
ES2903523T3 (es) 2022-04-04
HK1253322A1 (zh) 2019-06-14
US20160222022A1 (en) 2016-08-04
US10457652B2 (en) 2019-10-29
TW201636334A (zh) 2016-10-16
SA517382027B1 (ar) 2021-06-15
CN107873023B (zh) 2021-07-23
US10494353B2 (en) 2019-12-03
US10421731B2 (en) 2019-09-24
US20190016693A1 (en) 2019-01-17
EA201792673A1 (ru) 2018-04-30
US10479772B2 (en) 2019-11-19
TWI697486B (zh) 2020-07-01
TWI768557B (zh) 2022-06-21
IL279830A (en) 2021-01-31
US20200048212A1 (en) 2020-02-13
US20220363651A1 (en) 2022-11-17
EP3292116A1 (en) 2018-03-14
EP3292116B1 (en) 2021-10-20
US10513501B2 (en) 2019-12-24
CA2975605A1 (en) 2016-08-11
US10472337B2 (en) 2019-11-12
US10494351B2 (en) 2019-12-03
US20190119228A1 (en) 2019-04-25
CN107801396B (zh) 2021-10-22
IL253652B (en) 2021-03-25
US11274085B2 (en) 2022-03-15
US20190119227A1 (en) 2019-04-25
SG11201708622UA (en) 2017-11-29
JP6668362B2 (ja) 2020-03-18
US10442776B2 (en) 2019-10-15
WO2016126724A1 (en) 2016-08-11
CA2975605C (en) 2023-12-12
IL253652A0 (en) 2017-09-28
SG10202100915RA (en) 2021-02-25
PL3292116T3 (pl) 2022-02-21
US20210009538A1 (en) 2021-01-14
US20190112280A1 (en) 2019-04-18
US20210009540A1 (en) 2021-01-14
US20200055830A1 (en) 2020-02-20
EP4015514A1 (en) 2022-06-22
US10829462B2 (en) 2020-11-10
US20190119233A1 (en) 2019-04-25
US10112915B2 (en) 2018-10-30
EA036711B1 (ru) 2020-12-10
WO2016126725A1 (en) 2016-08-11
US20190112284A1 (en) 2019-04-18
AU2016215431A1 (en) 2018-01-18
US10450283B2 (en) 2019-10-22
CA2990165C (en) 2023-12-12
MX2020003488A (es) 2022-05-24

Similar Documents

Publication Publication Date Title
IL280856A (en) 3-Alkyl-4-amino-[0,5,4] bicyclic hydroxamic acids as HDAC inhibitors
IL288232A (en) 1,7- naphthyridine as immunomodulators
IL282103A (en) Furinones as ubiquitin-specific protease 1 inhibitors
HK1259073A1 (zh) 作為己酮糖激酶抑制劑的被取代的3-氮雜雙環[3‧1‧0]己烷
HK1245266A1 (zh) 作為usp30抑制劑的1-氰基吡咯烷化合物
HK1248222A1 (zh) 噻吩並嘧啶酮作為泛素特異性蛋白酶7抑制劑
EP3303324A4 (en) Novel corrosion inhibitors
IL265138B (en) Dopamine-b-hydroxylase inhibitors that penetrate the blood-brain barrier
EP3139918A4 (en) Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors
EP3153582A4 (en) Improved nitrile hydratase
IL255024A0 (en) Hydroxamic acids and their uses
GB201616201D0 (en) Blood-brain barrier-penetrant dopamine-B-hydroxylase inhibitors
GB201521588D0 (en) Fft 1
EP3282012A4 (en) Improved variants of cellobiohydrolase 1
GB201520946D0 (en) Active tagging
AU2015901305A0 (en) Improved anchor point